Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Prina Donga, Bruno Emond, Carmine Rossi, Brahim K Bookhart, Johnnie Lee, Gabrielle Caron-Lapointe, Fangzhou Wei & Marie-Hélène Lafeuille. (2023) Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1. ClinicoEconomics and Outcomes Research 15, pages 579-591.
Read now
Read now
Babafemi O. Taiwo, Hela Romdhani, Marie-Hélène Lafeuille, Rhea Bhojwani, Katherine Milbers & Prina Donga. (2023) Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews. Journal of Drug Assessment 12:1, pages 1-11.
Read now
Read now
Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, Brahim Bookhart, David Anderson, Patrick Lefebvre, Marie-Hélène Lafeuille & Prina Donga. (2022) Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Current Medical Research and Opinion 38:2, pages 287-298.
Read now
Read now
Articles from other publishers (14)
Samantha V. Hill, Jiaying Hao, Mia Newlin-Bradner, Dustin M. Long, Henna Budhwani & Tina Simpson. (2024) Re-evaluating the relationship between youth with HIV and BMI in an age of increasing rates of overweight and obese youth. BMC Research Notes 17:1.
Crossref
Crossref
José Antonio Mata Marín, Juan Carlos Velasco-Penagos, Stefan Mauss, Mara Soraya Rodriguez-Evaristo, Edgar Pérez-Barragán, Joaquín Villa-Platas, Laura Barragán-Huerta & Jesús Enrique Gaytán-Martínez. (2023) Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study. International Journal of STD & AIDS 35:1, pages 33-38.
Crossref
Crossref
Peter F. Rebeiro, Bruno Emond, Carmine Rossi, Brahim K. Bookhart, Aditi Shah, Gabrielle Caron‐Lapointe, Marie‐Hélène Lafeuille & Prina Donga. (2023) Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States. Journal of the International AIDS Society 26:6.
Crossref
Crossref
Giovanni Guaraldi, Paolo Bonfanti, Antonio Di Biagio, Andrea Gori, Jovana Milić, Paola Saltini, Francesco V. Segala, Nicola Squillace, Lucia Taramasso & Antonella Cingolani. (2023) Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda. BMC Infectious Diseases 23:1.
Crossref
Crossref
Prina Donga, Bruno Emond, Aditi Shah, Brahim K Bookhart, David Anderson, Maude Vermette-Laforme, Carmine Rossi & Marie-Hélène Lafeuille. (2023) Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors. Journal of Comparative Effectiveness Research 12:1.
Crossref
Crossref
Frank J. PalellaQingjiang HouJun LiJonathan MahnkenKimberly J. Carlson, Marcus DurhamDouglas WardJack FuhrerEllen Tedaldi, Richard NovakKate Buchacz. (2023) Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide. JAIDS Journal of Acquired Immune Deficiency Syndromes 92:1, pages 67-75.
Crossref
Crossref
Grace A. McComsey, Bruno Emond, Aditi Shah, Brahim K. Bookhart, Carmine Rossi, Katherine Milbers, Marie-Hélène Lafeuille & Prina Donga. (2022) Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy. Infectious Diseases and Therapy 11:5, pages 1883-1899.
Crossref
Crossref
Bruno Emond, Carmine Rossi, Rachel Rogers, Patrick Lefebvre, Marie-Hélène Lafeuille & Prina Donga. (2022) Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States. Journal of Health Economics and Outcomes Research 9:1, pages 39-49.
Crossref
Crossref
Yen-Wen Chen, David Anderson, Christopher D. Pericone & Prina Donga. (2022) Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors. Journal of Health Economics and Outcomes Research 9:1.
Crossref
Crossref
Yen-Wen Chen, David Anderson, Christopher Pericone & Prina Donga. (2022) Vol. 9, Issue 1, 2022 January 03, 2022 EDT Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors. Journal of Health Economics and Outcomes Research.
Crossref
Crossref
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Teresa Miani, Bianca Nuti, Isabella BonTiziana LazzarottoPierluigi Viale. (2022) Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir. AIDS 36:1, pages 153-155.
Crossref
Crossref
Carmine Rossi, Aurélie Côté-SergentKeith Dunn, Patrick LefebvreMarie-Hélène LafeuillePrina Donga & Bruno Emond. (2021) Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. Journal of Health Economics and Outcomes Research 8:1, pages 88-98.
Crossref
Crossref
Bruno EmondCarmine RossiAurélie Côté-SergentKeith Dunn, Patrick LefebvreMarie-Hélène LafeuillePrina Donga. (2021) Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. Journal of Health Economics and Outcomes Research 8:1, pages 88-98.
Crossref
Crossref
Bruno EmondCarmine RossiAurélie Côté-SergentKeith Dunn, Patrick LefebvreMarie-Hélène LafeuillePrina Donga. (2021) Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. Journal of Health Economics and Outcomes Research 8:1.
Crossref
Crossref